Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Keulen

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Journal of Virology|April 1, 1997
Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptaseW Keulen, N K Back, A van Wijk, et al.
Journal of Virology|July 1, 1992
Evolution of the V3 envelope domain in proviral sequences and isolates of human immunodeficiency virus type 1 during transition of the viral biological phenotypeC L Kuiken, J J de Jong, E Baan, et al.
Journal of Virology|September 1, 1992
Evolution of the V3 envelope domain in proviral sequences and isolates of human immunodeficiency virus type 1 during transition of the viral biological phenotypeC L Kuiken, J J de Jong, E Baan, et al.
Virology|March 1, 1994
An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralizationN K Back, L Smit, J J De Jong, et al.
Journal of Virology|February 1, 1992
Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacityJ J de Jong, J Goudsmit, W Keulen, et al.
AIDS (London, England)|June 1, 1990
Characterization of the African HIV-1 isolate CBL-4 (RUT) by partial sequence analysis and virus neutralization with peptide antibody and antisense phosphate-methylated DNAJ Goudsmit, J Geelen, W Keulen, et al.
The Journal of Infectious Diseases|August 1, 1997
Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivoM Nijhuis, R Schuurman, D de Jong, et al.
Antimicrobial Agents and Chemotherapy|October 1, 1996
Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assayC A Boucher, W Keulen, T van Bommel, et al.
The EMBO Journal|August 1, 1996
Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzymeN K Back, M Nijhuis, W Keulen, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Journal of Virology|April 1, 1997
Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptaseW Keulen, N K Back, A van Wijk, et al.
Journal of Virology|July 1, 1992
Evolution of the V3 envelope domain in proviral sequences and isolates of human immunodeficiency virus type 1 during transition of the viral biological phenotypeC L Kuiken, J J de Jong, E Baan, et al.
Journal of Virology|September 1, 1992
Evolution of the V3 envelope domain in proviral sequences and isolates of human immunodeficiency virus type 1 during transition of the viral biological phenotypeC L Kuiken, J J de Jong, E Baan, et al.
Virology|March 1, 1994
An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralizationN K Back, L Smit, J J De Jong, et al.
Journal of Virology|February 1, 1992
Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacityJ J de Jong, J Goudsmit, W Keulen, et al.
AIDS (London, England)|June 1, 1990
Characterization of the African HIV-1 isolate CBL-4 (RUT) by partial sequence analysis and virus neutralization with peptide antibody and antisense phosphate-methylated DNAJ Goudsmit, J Geelen, W Keulen, et al.
The Journal of Infectious Diseases|August 1, 1997
Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivoM Nijhuis, R Schuurman, D de Jong, et al.
Antimicrobial Agents and Chemotherapy|October 1, 1996
Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assayC A Boucher, W Keulen, T van Bommel, et al.
The EMBO Journal|August 1, 1996
Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzymeN K Back, M Nijhuis, W Keulen, et al.
Pageof 2